141.23 million baht or 48.54 % when compared with Q1 / 2022 which cost of sales increased accord with the increase revenue. Profit (Loss) Net Equity of shareholders of the Company for Q1/2023 and Q1/2022
ted company mbining the va s entered int rcent. Accord ited (“the ary shares nsurance, e detail of ix from s which -up enhance by using diligence with those with the alue of the to by the dingly, the
sold increased 24.47 percent from the same period of last year, which accord with higher sales volume. Selling expenses on year 2017 and 4th quarter increased 29.14 and 67.67 percent accordingly from the
, recipient countries of those foreign inflows, should be cautious of possible asset price fluctuation associated with capital surge, caused particularly by carry trade strategy. To cope with such situation
, however, the Company had new non-revolving USD working capital facility 30.0 million USD with Link Capital I (Mauritius) Limited. Liabilities under rehabilitation plan and compromise agreement increase
savings in the fund, a 69.8% soar over year end 2010, which accounts for 4,889 million baht, or a surge of 96.3%. These figures showed a good sign as members paid attention to systematic long-term savings
keep their B3,013 million of benefits in the system accounted for a 11.3% and 20.9% surge of members and benefits, respectively, over year-end 2010. This is a good sign showing that members give priority
14.36 hrs. on September 26, 2011, SET Index was at 867.94 and soared six minutes after the reopenning. SET Index?s closed at 904.06, or a surge of 36.12, a 4.16 percent rise after the halt. It was found
last year, while gross profit margin was slightly strengthened from 6.83% in 1H/2016 to 7.89% in 1H/2017. Other income in 1H/2017 amounted to Baht 741.35 million, a surge by Baht 375.49 million or 102.63
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million